Clinical trial
A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Tersolisib in Participants With Renal Impairment Compared With Participants With Normal Renal Function
NCT07924930 is registered in ClinicalTrials.gov with Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Tersolisib in Participants With Renal Impairment Compared With Participants With Normal Renal Function
- Lead sponsor
- Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- August 31, 2027
- Enrollment
- 32 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
healthy participant, renal insufficiency
Arms
As registered; 3 arms.
-
Tersolisib Group 1 (Normal Renal Function)
Tersolisib administered orally to participants with normal renal function
-
Tersolisib Group 2 (Severe Renal Impairment)
Tersolisib administered orally to participants with severe renal impairment
-
Tersolisib Group 3 (Moderate Renal Impairment, Optional)
Tersolisib administered orally to participants with moderate renal impairment
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tersolisib
-
PK: Area Under the Concentration Versus Time Curve (AUC) of Tersolisib
Lead sponsor's other trials
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, most recent start first.
Similar trials
Same condition (Renal Insufficiency, Chronic) and phase, most recent start first.
+183 more trials See the condition page